TCIM
HAE icon

TIAA CREF Investment Management’s Haemonetics HAE Stock Holding History

TIAA CREF Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$22.4M Sell
256,366
-42,323
-14% -$3.85M 0.02% 670
2018
Q4 		$29.9M Sell
298,689
-12,849
-4% -$1.35M 0.02% 523
2018
Q3 		$35.7M Sell
311,538
-11,861
-4% -$1.23M 0.02% 537
2018
Q2 		$29M Sell
323,399
-62,991
-16% -$5.32M 0.02% 601
2018
Q1 		$28.3M Buy
386,390
+116,193
+43% +$7.97M 0.02% 608
2017
Q4 		$15.7M Buy
270,197
+106,740
+65% +$5.62M 0.01% 898
2017
Q3 		$7.33M Buy
163,457
+2,528
+2% +$105K 0.01% 1368
2017
Q2 		$6.36M Sell
160,929
-47,528
-23% -$1.95M ﹤0.01% 1436
2017
Q1 		$8.46M Buy
208,457
+3,310
+2% +$129K 0.01% 1234
2016
Q4 		$8.25M Buy
205,147
+14,725
+8% +$555K 0.01% 1257
2016
Q3 		$6.89K Sell
190,422
-4,809
-2% -$165K ﹤0.01% 1383
2016
Q2 		$5.66M Sell
195,231
-39,582
-17% -$1.2M ﹤0.01% 1445
2016
Q1 		$8.21M Buy
234,813
+40,032
+21% +$1.29M 0.01% 1170
2015
Q4 		$6.28M Buy
194,781
+16,967
+10% +$550K ﹤0.01% 1383
2015
Q3 		$5.75M Sell
177,814
-8,982
-5% -$338K ﹤0.01% 1449
2015
Q2 		$7.73M Sell
186,796
-32,562
-15% -$1.37M 0.01% 1349
2015
Q1 		$9.85M Sell
219,358
-3,744
-2% -$157K 0.01% 1148
2014
Q4 		$8.35M Sell
223,102
-9,677
-4% -$354K 0.01% 1252
2014
Q3 		$8.13M Sell
232,779
-6,387
-3% -$228K 0.01% 1239
2014
Q2 		$8.44M Buy
239,166
+33,426
+16% +$1.12M 0.01% 1288
2014
Q1 		$6.71M Sell
205,740
-7,280
-3% -$278K ﹤0.01% 1407
2013
Q4 		$8.97M Sell
213,020
-1,590
-0.7% -$65.4K 0.01% 1222
2013
Q3 		$8.56M Sell
214,610
-1,977
-0.9% -$82.9K 0.01% 1193
2013
Q2 		$8.96M Buy
+216,587
New +$8.77M 0.01% 1115

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

TIAA CREF Investment Management's HAE Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Haemonetics (HAE) stake by 14% in Q1 2019, selling an estimated $3.85M and leaving 256,366 shares worth $22.4M. The position accounts for 0.02% of the portfolio, ranked #670.

TIAA CREF Investment Management first reported a position in HAE in Q2 2013 and has held it in 24 quarters since. The position peaked at $35.7M in Q3 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

  • TIAA CREF Investment Management held 256,366 shares of Haemonetics worth $22.4M as of Q1 2019.
  • TIAA CREF Investment Management sold 42,323 Haemonetics shares in Q1 2019, an estimated $3.85M.
  • Haemonetics made up 0.02% of TIAA CREF Investment Management's portfolio in Q1 2019, its #670 holding.
  • TIAA CREF Investment Management first reported a position in Haemonetics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Haemonetics position peaked at $35.7M in Q3 2018.
  • 260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.